Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer

Personalized neoantigen vaccines have shown strong immunogenicity in clinical trial, but still face various challenges in facilitating an efficient antitumor immune response. Here, a personalized neoantigen nanovaccine (PNVAC) platform for adjuvant cancer immunotherapy is generated. PNVAC triggers s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qin, Chu, Yanhong, Shao, Jie, Qian, Hanqing, Yang, Ju, Sha, Huizi, Cen, Lanqi, Tian, Manman, Xu, Qiuping, Chen, Fangjun, Yang, Yang, Wang, Weifeng, Wang, Kai, Yu, Lixia, Wei, Jia, Liu, Baorui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811442/
https://www.ncbi.nlm.nih.gov/pubmed/36351249
http://dx.doi.org/10.1002/advs.202203298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811442/
https://www.ncbi.nlm.nih.gov/pubmed/36351249
http://dx.doi.org/10.1002/advs.202203298

Ejemplares similares